Trace Neuroscience vs IBM
Side-by-side comparison of AI visibility scores, market position, and capabilities
Launched with $101M Series A (Third Rock, Atlas, GV, RA Capital). TRCN-1023 (ASO for UNC13A mRNA splicing) entered ALS clinical testing in early 2026 — skipping healthy volunteer phase. Targets 97% of ALS patients.
About
Trace Neuroscience launched with $101 million in Series A financing from Third Rock Ventures, Atlas Venture, GV (Google Ventures), and RA Capital Management, developing TRCN-1023 — an antisense oligonucleotide (ASO) that corrects UNC13A mRNA splicing defects that have been genetically validated as a driver of ALS (amyotrophic lateral sclerosis). The company went directly to ALS patient enrollment in early 2026, bypassing the healthy volunteer phase typical of first-in-human trials, reflecting confidence in the mechanism's tolerability profile.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
About
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Trace Neuroscience vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.